Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease

Description

This is a multicenter longitudinal study in about 300 patients with Idiopathic Parkinson's disease, who will be evaluated in several clinical centers with a clinical assessment and an oculometric examination during a time period with specific intervals. This study aims to evaluate the correlation between oculometric measures and clinical assessment over time, as well as the potential to detect early change in clinical status using an oculometric assessment.

Conditions

Parkinson Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a multicenter longitudinal study in about 300 patients with Idiopathic Parkinson's disease, who will be evaluated in several clinical centers with a clinical assessment and an oculometric examination during a time period with specific intervals. This study aims to evaluate the correlation between oculometric measures and clinical assessment over time, as well as the potential to detect early change in clinical status using an oculometric assessment.

A Multicenter Longitudinal Study to Evaluate the Correlation Between Oculometric Measures and Clinical Assessment in Patients With Idiopathic Parkinson's Disease (PALOMA Trial)

Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease

Condition
Parkinson Disease
Intervention / Treatment

-

Contacts and Locations

Chicago

Rush University, Chicago, Illinois, United States, 60612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Men and women with idiopathic PD (Hoehn \& Yahr scale 1-2)
  • * Age between 40 and 85 years old
  • * 0 to 5 years' time since diagnosis
  • * Normal or corrected vision
  • * Ability to follow instructions
  • * Willing and able to sign an informed consent form
  • * No anticipated changes in PD medications from baseline throughout the study duration based on clinical status during screening
  • * If treated, stable on treatment for at least 3 months
  • * Inability to sit for 40 minutes on a chair in a calm manner
  • * Personal or 1st degree relative history of epilepsy
  • * Additional neurological diseases
  • * Drug or alcohol abuse (except for using medical cannabis during 24 hours prior NL examination date)
  • * Pregnancy or a potential pregnancy (self-declaration)

Ages Eligible for Study

40 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NeuraLight,

Christina Januário, MD, PRINCIPAL_INVESTIGATOR, University of Coimbra

Richard Armstrong, MD, PRINCIPAL_INVESTIGATOR, The VCTC

Pablo Mir, MD, PRINCIPAL_INVESTIGATOR, Instituto de Biomedicina de Sevilla (IBiS

Michelle Tosin, PhD, PRINCIPAL_INVESTIGATOR, Rush Medical University Center

Bettina Balint, MD, PRINCIPAL_INVESTIGATOR, University Hospital, Zürich

Study Record Dates

2024-11-15